Pulmonary Embolism Treatment

For decades, pulmonary embolism treatment followed a rigid protocol: intravenous unfractionated heparin (UFH) bridged to warfarin, requiring hospitalization, frequent laboratory monitoring, and months of INR management. Low-molecular-weight heparins (LMWH) simplified initial treatment with predictable pharmacokinetics and subcutaneous dosing, but patients still required warfarin bridging. The recognition that PE spans an enormous severity spectrum — from incidental subsegmental findings to cardiovascular collapse — highlighted the need for risk-stratified management rather than one-size-fits-all hospitalization. The simplified Pulmonary Embolism Severity Index (sPESI) provided a validated tool to identify low-risk PE patients who could potentially be managed as outpatients, challenging the dogma that all PE required inpatient anticoagulation.

The direct oral anticoagulants (DOACs) revolutionized PE treatment by eliminating the need for parenteral bridging and INR monitoring. The EINSTEIN-PE trial (rivaroxaban), Hokusai-VTE (edoxaban), and AMPLIFY (apixaban) trials each demonstrated non-inferiority to conventional heparin-warfarin therapy for VTE recurrence, with significantly less major bleeding — particularly intracranial hemorrhage. EINSTEIN-PE (n=4,832) showed rivaroxaban was non-inferior with a 51% reduction in major bleeding. AMPLIFY (n=5,395) demonstrated apixaban was non-inferior with a 69% reduction in major bleeding. These trials transformed PE from a disease requiring complex anticoagulation management to one treatable with a single oral agent from day one. The simplicity of DOACs also facilitated the shift toward outpatient PE management.

Two parallel developments further refined PE management. First, outpatient PE treatment was validated by the Hestia criteria and multiple prospective studies demonstrating that low-risk PE patients (sPESI 0, no RV dysfunction, stable hemodynamics) could be safely discharged within 24-48 hours or even from the emergency department with DOAC therapy, with VTE recurrence and mortality rates <2%. The HOME-PE trial (n=1,975) confirmed that Hestia-guided outpatient management was non-inferior to hospitalization. Second, catheter-directed therapy (CDT) emerged for submassive and massive PE: the ULTIMA and SEATTLE II trials demonstrated that ultrasound-assisted catheter-directed thrombolysis with low-dose tPA could rapidly reduce RV dilation and pulmonary artery pressures with lower bleeding risk than systemic thrombolysis. Mechanical thrombectomy devices (FlowTriever, Indigo) expanded interventional options further, prompting the development of PE response teams (PERTs) for multidisciplinary triage.

The ESC 2019 guidelines and ASH 2020 guidelines recommend DOACs (apixaban or rivaroxaban) as first-line anticoagulation for PE in most patients, reserving LMWH/warfarin for specific situations (antiphospholipid syndrome, severe renal impairment, active cancer where LMWH or edoxaban/rivaroxaban preferred). Both guidelines endorse risk stratification using sPESI, troponin, and imaging (RV dysfunction on CT or echo) to categorize patients as low-risk (outpatient eligible), intermediate-low risk (short hospitalization), intermediate-high risk (consider escalation), or high-risk (systemic thrombolysis or catheter intervention). PERT teams are recommended for submassive and massive PE to guide multidisciplinary decision-making. Extended anticoagulation beyond 3-6 months is recommended for unprovoked PE, with DOACs at reduced dose (apixaban 2.5mg BID, rivaroxaban 10mg daily) supported by the AMPLIFY-EXT and EINSTEIN-Choice trials.

PE management in 2025-2026 exemplifies risk-stratified, personalized medicine. Low-risk patients are increasingly managed entirely as outpatients with single-drug DOAC therapy. PERT teams have proliferated at major centers, providing 24/7 multidisciplinary decision support for intermediate- and high-risk PE. Catheter-directed therapies continue to evolve rapidly, with the FLARE, FLASH, and HI-PEITHO trials evaluating mechanical thrombectomy and low-dose CDT for submassive PE. The debate around treating intermediate-risk (submassive) PE with more aggressive interventions remains the most active area of research. Biomarker-guided risk stratification is being refined with serial troponin, BNP, and lactate measurements. Extended and indefinite anticoagulation decision-making is increasingly supported by prediction models (HERDOO2, Vienna, DASH) that estimate individual recurrence risk to guide duration. Cancer-associated PE management has been refined with DOAC-specific trials (SELECT-D, Caravaggio).